AtaiBeckley Inc. Common Stock (ATAI) Stock Price

ATAIStock

$7.35−65.30%52W

Market Cap$2.73B

P/E—

PEG Ratio—

Div yield—

Beta0.03

ATAI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)104.11%

Price vs S&P 500 (4W)3.96%

VGM Score54.86

Book Value / Share (Quarterly)$0.48

P/TBV (Annual)6.78x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)160.99%

Cash Flow / Share (Quarterly)$-0.36

Price vs S&P 500 (YTD)68.57%

Net Profit Margin (TTM)-14938.36%

EPS (TTM)$-2.18

10-Day Avg Trading Volume19.92M

EPS Excl Extra (TTM)$-2.18

EPS (Annual)$-2.91

ROI (Annual)-297.49%

Net Profit Margin (5Y Avg)-28899.22%

Cash / Share (Quarterly)$0.61

Revenue Growth QoQ (YoY)137.00%

ROA (Last FY)-225.49%

Revenue Growth TTM (YoY)93.30%

EBITD / Share (TTM)$-2.12

ROE (5Y Avg)-109.07%

Operating Margin (TTM)-14872.37%

Cash Flow / Share (Annual)$-0.31

P/B Ratio15.46x

P/B Ratio (Quarterly)11.00x

Net Income / Employee (Annual)$-6,667,100

EV / Revenue (TTM)571.66x

Net Interest Coverage (TTM)-40.12x

ROA (TTM)-251.62%

EPS Incl Extra (Annual)$-2.91

Current Ratio (Annual)11.74x

Quick Ratio (Quarterly)8.35x

3-Month Avg Trading Volume11.54M

52-Week Price Return-65.30%

Revenue / Employee (TTM)$45,200

Tangible BV / Share (Quarterly)$0.47

P/S Ratio (Annual)666.63x

Asset Turnover (Annual)0.01x

52-Week High$7.45

Operating Margin (5Y Avg)-29988.13%

EPS Excl Extra (Annual)$-2.91

CapEx CAGR (5Y)182.88%

26-Week Price Return116.81%

Quick Ratio (Annual)11.56x

13-Week Price Return88.95%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.58x

Enterprise Value$2.56B

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$41,300

Pretax Margin (Annual)-16137.17%

Cash / Share (Annual)$0.70

3-Month Return Std Dev85.99%

Net Income / Employee (TTM)$-6,749,400

ROE (Last FY)-297.49%

Net Interest Coverage (Annual)-114.81x

EPS Basic Excl Extra (Annual)$-2.91

Receivables Turnover (TTM)0.05x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.18

Receivables Turnover (Annual)0.03x

ROI (TTM)-353.23%

P/S Ratio (TTM)609.40x

Pretax Margin (5Y Avg)-27255.25%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.60

Price vs S&P 500 (52W)-69.35%

Year-to-Date Return79.71%

5-Day Price Return0.14%

EPS Normalized (Annual)$-2.91

ROA (5Y Avg)-84.65%

Net Profit Margin (Annual)-16142.02%

Month-to-Date Return0.14%

Cash Flow / Share (TTM)$-0.41

EBITD / Share (Annual)$-2.81

Operating Margin (Annual)-15582.27%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-103.88%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.18

P/TBV (Quarterly)11.17x

P/B Ratio (Annual)6.70x

Pretax Margin (TTM)-14937.47%

Book Value / Share (Annual)$0.61

Price vs S&P 500 (13W)86.13%

Beta0.03x

Revenue / Share (TTM)$0.01

ROE (TTM)-353.23%

52-Week Low$3.27

vGradeF

gGradeA

mGradeB

vgmGradeC

ATAI Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.11	-$0.09	+19.45%(+$0.02)
Q4 2025	Mar 6, 2026	-$0.11	-$1.73	-1441.61%(-$1.62)
Q3 2025	Nov 12, 2025	-$0.12	-$0.28	-125.28%(-$0.16)
Q2 2025	Aug 14, 2025	-$0.12	-$0.14	-18.31%(-$0.02)

ATAI Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.20

4.24

3.57

3.43

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ATAIAtaiBeckley Inc. Common Stock	F	A	B	609.4x	93.3%	—	—	$7.35
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About AtaiBeckley Inc. Common Stock

AtaiBeckley Inc is a clinical-stage biopharmaceutical company developing novel therapies for psychiatric disorders, with a focus on rapid-acting and convenient treatment options. The company's Phase 2 pipeline includes three candidates: BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, VLS-01 (DMT buccal film) for treatment-resistant depression and social anxiety disorder, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. These programs address significant unmet medical needs in mental health treatment.

ATAI Next Earnings Report

Report dateNov 12, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.12

Revenue estimate$218,180

Also reporting on Nov 12, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

SMGThe Scotts Miracle-Gro CompanyAgricultural Chemicals
COTYCOTY INCCosmetics & Toiletries
DNLIDenali Therapeutics Inc. Common StockBiological Products
FULH.B. Fuller CompanyAdhesives & Sealants
WDFCWd-40 CoIndustrial Chemicals
NEOGNeogen CorpIn Vitro Diagnostics
BEAMBeam Therapeutics Inc. Common StockBiological Products
NGVTIngevity CorporationChemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.4

Buy

Consensus rating

52-Week Range

Low$3.27

High$7.45